871 related articles for article (PubMed ID: 23772082)
21. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures.
Jolly M; Kazmi N; Mikolaitis RA; Sequeira W; Block JA
J Am Acad Dermatol; 2013 Apr; 68(4):618-623. PubMed ID: 23107310
[TBL] [Abstract][Full Text] [Related]
22. Prospective Validation of the Lupus Impact Tracker: A Patient-Completed Tool for Clinical Practice to Evaluate the Impact of Systemic Lupus Erythematosus.
Jolly M; Kosinski M; Garris CP; Oglesby AK
Arthritis Rheumatol; 2016 Jun; 68(6):1422-31. PubMed ID: 26814452
[TBL] [Abstract][Full Text] [Related]
23. The Rheumatology Attitudes Index and its helplessness subscale are valid and reliable measures of learned helplessness in Asian patients with systemic lupus erythematosus.
Thumboo J; Fong KY; Chan SP; Leong KH; Feng PH; Thio ST; Boey ML
J Rheumatol; 1999 Jul; 26(7):1512-7. PubMed ID: 10405938
[TBL] [Abstract][Full Text] [Related]
24. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.
Aggarwal R; Wilke CT; Pickard AS; Vats V; Mikolaitis R; Fogg L; Block JA; Jolly M
J Rheumatol; 2009 Jun; 36(6):1209-16. PubMed ID: 19369452
[TBL] [Abstract][Full Text] [Related]
25. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
[TBL] [Abstract][Full Text] [Related]
26. Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients.
Pamuk ON; Onat AM; Donmez S; Mengüs C; Kisacik B
Lupus; 2015 Jul; 24(8):816-21. PubMed ID: 25542903
[TBL] [Abstract][Full Text] [Related]
27. Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus.
Jolly M; Sequeira W; Block JA; Toloza S; Bertoli A; Blazevic I; Vila LM; Moldovan I; Torralba KD; Mazzoni D; Cicognani E; Hasni S; Goker B; Haznedaroglu S; Bourre-Tessier J; Navarra SV; Mok CC; Weisman M; Clarke AE; Wallace D; Alarcón G
Arthritis Care Res (Hoboken); 2019 Dec; 71(12):1647-1652. PubMed ID: 29693320
[TBL] [Abstract][Full Text] [Related]
28. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS
J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356
[TBL] [Abstract][Full Text] [Related]
29. Lupus-specific health outcome measure for US patients: the LupusQoL-US version.
Jolly M; Pickard AS; Wilke C; Mikolaitis RA; Teh LS; McElhone K; Fogg L; Block J
Ann Rheum Dis; 2010 Jan; 69(1):29-33. PubMed ID: 19126561
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life in portuguese SLE patients: an outcome measure independent of disease activity and cumulative damage.
Duarte C; Abreu P; Couto M; Vaz C; Malcata A; Inês L
Acta Reumatol Port; 2010; 35(1):30-5. PubMed ID: 20518146
[TBL] [Abstract][Full Text] [Related]
31. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus.
Stoll T; Stucki G; Malik J; Pyke S; Isenberg DA
J Rheumatol; 1997 Feb; 24(2):309-13. PubMed ID: 9034988
[TBL] [Abstract][Full Text] [Related]
32. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus.
Devilliers H; Amoura Z; Besancenot JF; Bonnotte B; Pasquali JL; Wahl D; Maurier F; Kaminsky P; Pennaforte JL; Magy-Bertrand N; Arnaud L; Binquet C; Guillemin F
Rheumatology (Oxford); 2012 Oct; 51(10):1906-15. PubMed ID: 22826305
[TBL] [Abstract][Full Text] [Related]
33. Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.
Giangreco D; Devilliers H; Annapureddy N; Block JA; Jolly M
Lupus; 2015 Dec; 24(14):1486-91. PubMed ID: 26162686
[TBL] [Abstract][Full Text] [Related]
34. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
Castrejón I; Tani C; Jolly M; Huang A; Mosca M
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
[TBL] [Abstract][Full Text] [Related]
35. Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings.
Schneider M; Mosca M; Pego-Reigosa JM; Gunnarsson I; Maurel F; Garofano A; Perna A; Porcasi R; Devilliers H
Rheumatology (Oxford); 2017 May; 56(5):818-828. PubMed ID: 28204765
[TBL] [Abstract][Full Text] [Related]
36. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity.
Neville C; Clarke AE; Joseph L; Belisle P; Ferland D; Fortin PR
J Rheumatol; 2000 Mar; 27(3):675-9. PubMed ID: 10743807
[TBL] [Abstract][Full Text] [Related]
37. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
38. Validation of the Lupus Impact Tracker in an Australian patient cohort.
Antony A; Kandane-Rathnayake RK; Ko T; Boulos D; Hoi AY; Jolly M; Morand EF
Lupus; 2017 Jan; 26(1):98-105. PubMed ID: 27516435
[TBL] [Abstract][Full Text] [Related]
39. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients.
FitzGerald JD; Grossman JM
Lupus; 1999; 8(8):638-44. PubMed ID: 10568901
[TBL] [Abstract][Full Text] [Related]
40. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore.
Thumboo J; Fong KY; Ng TP; Leong KH; Feng PH; Thio ST; Boey ML
J Rheumatol; 1999 Jan; 26(1):97-102. PubMed ID: 9918248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
